IQWiG – Systematic Assessment of Medical Evidence

What is IQWiG?

The Institute for Quality and Efficiency in Health Care, known as IQWiG, examines the benefits and harms of medical interventions. It produces scientific assessments and understandable health information. Its work uses evidence-based medicine methods to evaluate existing research systematically.

IQWiG is not a marketing authorization authority. Its assessments also do not generally involve conducting its own clinical treatment trials; the institute examines the evidence available for the question concerned.

Why is IQWiG relevant to pharmaceutical companies?

For many German early benefit assessment procedures, IQWiG prepares a dossier assessment commissioned by the G-BA. It examines the submitted evidence against the relevant assessment question. The G-BA makes the final decision in the procedure.

Companies therefore need to consider more than whether a study reports positive findings. Population, comparator, outcomes and analysis must also suit the particular question. This perspective is most useful when considered early in evidence planning rather than only during dossier preparation.

How should an IQWiG assessment be interpreted?

Several questions help readers understand the methodology and procedural context.

• Mandate: What question is being addressed, and which population is concerned?
• Evidence base: Which studies and documents were considered, and why were others excluded?
• Findings: Which patient-relevant benefits and harms can be supported by the suitable evidence?
• Confidence: What uncertainty, risks of bias and limitations are described?

Document type also matters. A dossier assessment, a rapid report and a public health information resource have different functions and audiences. They should not be treated as interchangeable forms of the same decision.

What communication challenges arise?

An isolated finding can be misunderstood without its methodological explanation. Evidence being judged unsuitable does not automatically show that a medicine has no effect. It first indicates that the particular conclusion is not sufficiently supported by those data.

Editorial material should distinguish draft documents, final reports and subsequent decisions. Quotations need accurate attribution, while the writer's interpretation should remain identifiable as interpretation. Current original documents are preferable to abbreviated secondary accounts when explaining a complex assessment.

What makes an outcome patient-relevant?

Assessment examines mortality, symptoms and complications, adverse effects and health-related quality of life. A laboratory value is not automatically patient-relevant because it changes statistically. If used as a substitute for a clinical outcome, its validity for that purpose needs justification. Communication should therefore identify what was actually measured and which conclusion the assessment supports.

Conclusion: Read IQWiG findings through their methods

IQWiG supports decisions through systematic evidence assessment. Pharmaceutical and communication teams need to understand the question, evidence base and uncertainty. Together, these elements provide the context needed to describe a finding accurately.